Benzoazepine TLR7/8 Antagonists for Autoimmune Treatment
Solution Overview
Problem
Current therapies for modulating Toll-like receptor (TLR) 7 and 8 signaling lack effective compounds to inhibit their activation, which is crucial for treating conditions involving unwanted immune activity such as inflammatory and autoimmune disorders.
Innovation Solution
Development of specific compounds with the formula I and its pharmaceutically acceptable salts, which act as TLR7 and/or TLR8 antagonists, inhibiting the activation of these receptors with an IC50 of 25 µM or less, thereby modulating immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TLR7 and TLR8 agonists are used to stimulate immune responses, then immune activation is enhanced, but unwanted immune activity and inflammation increase
Solution Approach 1:
The patent applies preliminary anti-action by developing TLR7/8 antagonists that can block unwanted immune activation before it leads to harmful inflammatory responses. These antagonists are designed to inhibit TLR7 and TLR8 signaling pathways, preventing the cascade of immune activation that would otherwise result in adverse inflammatory outcomes. The antagonists serve as a preemptive measure to control immune responses while allowing beneficial immune function to proceed.
2Adaptability or versatility
If no effective TLR7/8 inhibitors are available, then therapeutic options for autoimmune disorders are limited, but conditions involving unwanted immune activity cannot be effectively treated
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of TLR7/8 antagonists to optimize their inhibitory potency and selectivity. By varying structural parameters such as the R groups attached to the core benzoazepine scaffold, the invention achieves compounds with IC50 values of 25 µM or less, representing a significant improvement in therapeutic efficacy. This systematic optimization of molecular parameters enables the development of effective treatments for autoimmune and inflammatory conditions.
3Reliability
If compounds with high TLR7/8 inhibitory potency are developed, then treatment efficacy for autoimmune disorders improves, but compound complexity increases
Solution Approach 1:
The patent applies local quality by introducing specific functional groups at particular positions on the benzoazepine core structure to achieve high TLR7/8 inhibitory potency. Rather than uniformly complicating the entire molecule, the invention strategically places specific R groups (such as halogens, alkyl chains, or aromatic substituents) at key positions that maximize interaction with the TLR7/8 binding site. This localized optimization achieves IC50 ≤ 25 µM while maintaining reasonable structural complexity.
Data Source
Figure 1
Figure 2(A)~2(K)
AI summary
Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, fibrotic disease, cardiovascular disease, infectious disease, inflammatory disorder, graft rejection, or graft-versus-host disease.